Dr. Dibyendu Banerjee serves as a Principal Scientist and Group Leader at the prestigious CSIR-Central Drug Research Institute (CSIR-CDRI) in Lucknow, Uttar Pradesh, India. He earned his Master’s degree from Banaras Hindu University, Varanasi, and his Ph.D. from Jawaharlal Nehru University, New Delhi. Subsequently, Dr. Banerjee undertook advanced research training in the United States, first at the University of Texas and later at the University of Maryland, Baltimore.

Since joining CSIR-CDRI in 2011, Dr. Banerjee has established and led his own research laboratory, specializing in the development of cancer therapeutics. His expertise lies in Cancer Biology, with a focus on studying DNA repair and replication proteins that cancer cells exploit for proliferation. His research aims to develop therapeutic agents that inhibit cancer cell growth.

Dr. Banerjee has authored over 50 research papers, reviews, and book chapters, contributing significantly to the fields of cancer biology and multidrug resistance (MDR). He holds several patents for potential cancer treatments in the USA, UK, France, Germany, and India.

Driven by the belief that "prevention is better than cure," Dr. Banerjee is dedicated to raising awareness about common cancer causes to help individuals avoid preventable cancers. He is also committed to education, teaching Cancer Biology to graduate and postgraduate students, and frequently delivering popular lectures and conducting workshops for both students and the general public.